RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, B...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2019
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/d47c9a0f1fb34d9fbf19d8fa3d9804b4 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|